<SEC-DOCUMENT>0001062993-17-001465.txt : 20170324
<SEC-HEADER>0001062993-17-001465.hdr.sgml : 20170324
<ACCEPTANCE-DATETIME>20170323181557
ACCESSION NUMBER:		0001062993-17-001465
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170322
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170324
DATE AS OF CHANGE:		20170323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		17710761

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>March 22,
2017</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="50%" align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="50%" ><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD width="50%" align=center>(Address of principal executive offices) </TD>
  <TD align=center width="50%" >(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250) 765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)<BR>
[&nbsp;&nbsp; ] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
[&nbsp;&nbsp; ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
[&nbsp;&nbsp; ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))<BR>
</P>
<TABLE width="100%" border=0 cellPadding=0
cellSpacing=0
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; ">
  <TR vAlign=top>
    <TD align=left><B>Item 7.01</B></TD>
    <TD width="90%" align=left ><B>Regulation FD Disclosure </B></TD>
  </TR>
</TABLE>
<P align=justify>A copy of the news release announcing the introduction of the
TurboCBD&#153; brand of technologically enhanced, high absorption full spectrum hemp
oil capsules is filed as exhibit 99.1 to this current report and is hereby
incorporated by reference. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 9.01</B></TD>
    <TD align=left ><B>Financial Statements and Exhibits </B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee ><a href="exhibit99-1.htm">Press Release
      dated March 22, 2017 </a></TD>
  </TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify>&nbsp;</P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: March 23, 2017 </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  </TABLE>
<BR>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B><font size="3">Lexaria Introduces TurboCBD&#153; Brand of High Absorption Full
Spectrum Hemp Oil Capsules </font></B></P>
<P align=justify>Kelowna, BC / March 22, 2017 / Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;) announces the introduction
of the TurboCBD&#153; brand of technologically enhanced, high absorption full
spectrum hemp oil capsules. Lexaria&#146;s TurboCBD&#153; capsules are specially
formulated with the finest American Ginseng and Ginkgo Biloba for support of
enhanced focus and memory, and reduced stress and fatigue.</P>
<P align=center><IMG src="graphic.jpg" border=0> </P>
<P align=justify>TurboCBD&#153; capsules utilize Lexaria&#146;s patented absorption
technology and are triple tested for purity. They are made without the use of
organic solvents and leave no hemp oil aftertaste. They are vegan, gluten-free,
sugar-free, nut-free and made in the USA. They will soon be offered for sale
through California medical cannabis dispensaries and other select locations as
the perfect complement to any cannabis regimen.</P>
<P align=justify>Lexaria&#146;s TurboCBD&#153; capsules are designed to work with the
physiology of the human gastrointestinal system where minute quantities of long
chain fatty acids like sunflower oil, combined in each serving of TurboCBD&#153;
capsules, are thoroughly and quickly absorbed into the circulatory system for
maximum effectiveness. <I>In vitro</I> and human focus study testing has shown
increases in CBD absorption using Lexaria&#146;s technology by as much as 5-10 times
more than conventional preparations. Those studies also demonstrated rapid onset
of action in as little as 15 minutes. </P>
<P align=justify>Lexaria intends to showcase its TurboCBD&#153; capsules at the
upcoming 2017 World Medical Marijuana Business Conference &amp; Expo in
Pittsburgh on April 21 and 22, which is expected to attract over 8,000 cannabis
professionals including 1,200 physicians interested in the sector. </P>
<P align=justify>Lexaria is
  further researching other capsule formulations utilizing its patented
  absorptiontechnology, each of which would be uniquely formulated to address
  specific market demands. Testing with Lexaria&#146;s technology has shown equally
  good improvements in enhancing absorption and rapidity of action when working with THC as
shown for CBD, and Lexaria continues to develop and seek opportunities to lever
its technology for THC product applications through licensees in the USA, Canada
and internationally. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify>About Lexaria <BR>
  Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Company&#146;s lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while also
improving taste. This technology promotes healthy ingestion methods, lower
overall dosing and higher effectiveness in active molecule delivery. The
Company&#146;s technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. </P>
<P align=justify><U><FONT color=#0000ff>www.lexariabioscience.com
</FONT></U><BR>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Chris Bunka<BR>Chairman &amp; CEO<BR>(250) 765-6424 <BR></P>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Access to capital,
or lack thereof, is a major risk and there is no assurance that the Company will
be able to raise required working capital. Factors which could cause actual
results to differ materially from those estimated by the Company include, but
are not limited to, government regulation, managing and maintaining growth, the
effect of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements. There is no assurance that any planned corporate activity, business
venture, or initiative will be pursued, or if pursued, will be successful. There
is no assurance that any of Lexaria&#146;s postulated uses, benefits, or advantages
for the patented and patent-pending technology will in fact be realized in any
manner or in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria Energy Foods and ViPova<SUP>TM </SUP>products
are not intended to diagnose, treat, cure or prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graphic.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graphic.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" $- ,,# 2(  A$! Q$!_\0
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M\:<++W/Y4 9JI>_\]A^52K%>_P#/<?E6@+0^M.%N1WH HK%=][@?E4@ANO\
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ME*UM --ZIW'2KC]*IW'0UF,;I7WI_J/ZUHUG:5]Z?ZC^M:- @HHHH *J7_\
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M# D]"<Y'Y5U876-VK,FM)REO<M36FAN99IHK<ESN<MW(SSC\Z?<#1[>P_?)
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M112U(#'JG<=*NOTJE<=*!C=*^]/]1_6M&L[2OO3_ %']:T:!!1110 54O_\
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M 6BHWFCC!9Y$4#N3BJCZQ81G!N%)_P!D$_RIJ+>R(=2*W9<?I5.XZ57DU^R
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M%3&J*W5V^,0*OU;-.Q>/U=$'^RN?YU-[EI);%L$#J:C>XB)VJVX^@J$63O\
MZR9V'IT%6(;9(N@I + A'+#&:NKTJ)5-3 8% "T444 %%%% #2H/:FM&#4E%
M %<Q#TIK0@]JM44 4C;K_=IAM$/5!5_ ]*3:/2@#.-E&?X!3381?\\Q6GM%)
ML]Z ,LZ?"?\ EF/RI/[.A_YYC\JU=GO1L]Z ,K^SH?\ GF/RI1I\0_Y9C\JU
M-GO1L]Z ,T6$7_/,?E3Q9QC^ ?E5_92[10!2%J@Z(/RIXA [5:VBEP/2@"N(
?AZ4X1BIL4M $(3VIX3%/HH 0 #I2T44 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
